7th TRP Europe | November 2025, Amsterdam | Agenda Released

Radioligand therapy is evolving rapidly.
With new targets like HER2 and FAP coming into focus, and promising data emerging beyond PSMA and SSTR2, real momentum is building in the field. But to truly unlock the potential of these therapies across Europe and integrate RLT as the next pillar of oncology treatment, we need more than scientific innovation. We need collaboration and harmonisation across the entire development journey.
The 7th Targeted Radiopharmaceuticals Summit Europe is here to make that happen.
Explore the BRAND-NEW programme here: https://ter.li/a5r9rv
This is the go-to meeting for anyone working to bring the next generation of targeted radiopharmaceuticals to patients, whether you're involved in early discovery, clinical development, manufacturing, or regulatory affairs. Designed with input from leaders across the RLT space, this year’s summit is packed with practical insights, honest conversations, and real-world solutions.
This year’s event is bigger, fresher, and more focused than ever, featuring brand-new content, including:
- 40+ expert speakers, including new key opinion leaders and biopharma innovators from Bayer, AstraZeneca, and Telix Pharmaceuticals
- The launch of a third content track, covering Discovery & Preclinical, Translational & Clinical, and CMC & Sourcing
- Six new RLT-centric workshops addressing radiopharmaceutical design, dosimetry translation, and more
While this is an exciting time for the industry, we recognise the challenges that come with rapid progress. That’s why we’re addressing them head-on, with in-depth discussions on:
- Novel target discovery, including the exploration of SSTR3, FAP, and more
Connect with 200+ peers who are advancing the field and share strategies and insights that will define the next chapter of RLT innovation.
Be part of the conversation as we shape the future of targeted radiopharmaceuticals together.